Chronos Therapeutics

About:

Chronos Therapeutics is a drug development company focused on the development of drugs for the treatment of age-related diseases.

Website: http://chronostherapeutics.com

Top Investors: Odey Asset Management, Vulpes Investment Management Pte Ltd, University of Oxford

Description:

Chronos Therapeutics’ drug development scheme focuses in two main areas: - Repositioning FDA approved drugs. - Screening, discovery and development of novel proprietary drug candidates. Current Targets - Diseases of Ageing: Osteoporosis, Cancer and Sarcopenia. - Neurodegenerative Diseases: Parkinson’s Disease, Alzheimer’s Disease, ALS and Orphan Synucleopathies. Chronos Therapeutics’ research is successfully advancing from pre-clinical stages of development for age-related disease treatments to clinical development. Chronos' pioneering drug discovery and development platform the Chronoscreen has enabled the company to quickly gain proprietary positions in the regulation of cellular chronological lifespan. Some of the most exciting and effective therapeutic approaches of the future will utilize our understanding of the biological programming of life-span and ageing that take place in every cell of our body. Harnessing this knowledge will lead to novel treatments for age related diseases such as Alzheimer's Disease, Diabetes, Cancer and Osteoporosis.

Total Funding Amount:

8M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Oxford, Oxfordshire, United Kingdom

Founded Date:

2009-01-01

Contact Email:

info(AT)chronostherapeutics.com

Founders:

Number of Employees:

11-50

Last Funding Date:

2013-12-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai